Arcutis Biotherapeutics, Inc. ARQT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s financing cash flow?
- Arcutis Biotherapeutics, Inc. (ARQT) reported financing cash flow of $1.07M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s financing cash flow changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s financing cash flow increased by 170.1% year-over-year, from $395K to $1.07M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s financing cash flow has grown at a -70.9% compound annual growth rate (CAGR), from $281.95M to $6.97M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.